VJHemOnc Podcast

In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only been possible with the use of high-dose therapy plus autologous stem cell transplantation. Novel agents are changing the treatment landscape, with combinations of daratumumab, dexamethasone, thalidomide, bortezomib and lenalidomide increasing the rates of complete remission and partial response compared to VAD.

In this podcast, the endless possible combinations are discussed by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Mohty gives us his insight into induction therapy and also where we may be going next.

The post Induction therapy in myeloma: an ever-changing paradigm appeared first on VJHemOnc.

The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods to monitor disease. One such example is the use of measurable residual disease (MRD) status to plan treatment, determine disease prognosis, and compare treatment efficacy. In terms of novel treatments, CAR T-cell therapy has proven promising for treating acute lymphoblastic leukemia, and will continue to be a key focus of research in the near future. In this podcast, Alan Burnett, MD, PhD, of Cardiff University, Cardiff, UK; Andrew Wei, MBBS, PhD, FRACP, FRCPA, of Monash University, Victoria, Australia; and Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discuss the future of acute leukemia therapy at the International Workshop on Acute Leukemias (iwAL) 2019 meeting held in Barcelona, Spain.

The post iwAL 2019: looking to the future of acute leukemia therapy appeared first on VJHemOnc.

This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology of the disease. This podcast features a recent discussion amongst acute leukemia experts from the International Workshop on Acute Leukemias (iwAL) 2019 conference held in Barcelona, Spain. In this podcast, Noelle Frey, MD , University of Pennsylvania, Philadelphia, PA; Bianca Santomasso, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY; and Wendy Stock, MD, of the University of Chicago Medicine, Chicago, IL, discuss a vast range of topics, including the improvement of patient outcomes, the use of CAR T-cell therapy and the importance of MRD in prognostics.

The post Acute leukemia: pushing boundaries in disease management appeared first on VJHemOnc.

Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with world-class lymphoma experts: Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on key updates from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The group explores the use of CAR T-cell therapy, considering the hurdles and benefits, and discusses the realm of precision medicine in this field.

The post CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma appeared first on VJHemOnc.

Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response to novel therapies, hence justifying the mass of attention MRD testing is receiving in multiple myeloma (MM). From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, chairs an insightful discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, and Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, on the promising prospects of emerging, highly sensitive techniques for MRD testing. This podcast covers the enthralling discussion between the trio as they also tackle the question of how far away MRD testing is from prime time and routine clinical use in MM.

The post MRD testing in multiple myeloma: new technology with promising clinical applications appeared first on VJHemOnc.